Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Vaverkova H, et al. Among authors: shah a. Cardiovasc Ther. 2012 Apr;30(2):61-74. doi: 10.1111/j.1755-5922.2010.00181.x. Epub 2010 Jul 7. Cardiovasc Ther. 2012. PMID: 20626402 Free article. Clinical Trial.
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Vaverkova H, et al. Among authors: shah a. Clin Biochem. 2011 Jun;44(8-9):627-34. doi: 10.1016/j.clinbiochem.2011.02.008. Epub 2011 Feb 22. Clin Biochem. 2011. PMID: 21349260 Clinical Trial.
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Averna M, Missault L, Vaverkova H, Farnier M, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Taggart W, Brudi P. Averna M, et al. Among authors: shah a. Diab Vasc Dis Res. 2011 Oct;8(4):262-70. doi: 10.1177/1479164111418136. Epub 2011 Aug 22. Diab Vasc Dis Res. 2011. PMID: 21859750 Free article. Clinical Trial.
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, Johnson-Levonas AO, Brudi P. Leiter LA, et al. Among authors: shah a. Diabetes Obes Metab. 2011 Jul;13(7):615-28. doi: 10.1111/j.1463-1326.2011.01383.x. Diabetes Obes Metab. 2011. PMID: 21332628
A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.
Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T; Vytorin Extension Study Group. Ose L, et al. Among authors: shah a. Int J Clin Pract. 2007 Sep;61(9):1469-80. doi: 10.1111/j.1742-1241.2007.01402.x. Epub 2007 Jul 26. Int J Clin Pract. 2007. PMID: 17655686 Clinical Trial.
12,090 results
You have reached the last available page of results. Please see the User Guide for more information.